FDA panel to focus on safety of Novartis gene therapy drug – Reuters
Reuters |
FDA panel to focus on safety of Novartis gene therapy drug
Reuters (Reuters) – The U.S. Food and Drug Administration will ask a panel of advisors to focus on the safety of Novartis AG's experimental gene therapy drug when it meets to review the product on Wednesday. The keenly anticipated preliminary review of the … FDA Advisory Board and Novartis to Discuss Leukemia Gene Therapy Wednesday Before Key Meeting, FDA Stresses Risks of Novartis CAR-T Cancer Therapy |
